Evaluate Amdocs' (DOX) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Evaluate IPG's (IPGP) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Examine Cirrus Logic's (CRUS) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.

Explore how Coty's (COTY) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Review Microchip Tech's (MCHP) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

ETFs are heading for another record year of inflows. Fixed income funds are playing significant parts in that influx of capital.

Explore MKS' (MKSI) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Examine the evolution of M/A-Com's (MTSI) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

Explore Teleflex's (TFX) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Examine the evolution of Eastman Chemical's (EMN) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

Evaluate Exelixis' (EXEL) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Explore how ON Semiconductor Corp.'s (ON) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Explore Cogent's (CCOI) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Explore how Tapestry's (TPR) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

NanoViricides (NYSE-A:NNVC) is advancing its broad-spectrum antiviral NV-387, backed by new financing that strengthens its balance sheet and supports regulatory progress toward Phase II trials for monkeypox in Central Africa. In its quarterly report for the quarter ended September 30, 2025, the clinical-stage biotech company said NV-387 is engineered to resist viral escape.

WALTHAM, Mass.--(BUSINESS WIRE)--Pegasystems Inc. (NASDAQ: PEGA), The Enterprise Transformation Company™, today announced Forrester Research named Pega a Leader in The Forrester Wave™: Real-Time Interaction Management Software (RTIMS), Q4 2025 report (1). Pega earned top scores in both the ‘Current Offering' and ‘Strategy' categories, and received the highest scores possible in 25 of the 28 total evaluation criteria. The report explains, “Pega's Customer Decision Hub (CDH) is a centralized RTIM.

PDD's Q3 reflects calculated investments amid competitive pressures. Strategic patience warranted - hold positions or await post-earnings valuations.

A busy period is ahead for Arrowhead Pharmaceuticals on regulatory, legal, and clinical fronts. The PDUFA date with the FDA for plozasiran is tomorrow, and an approval should be expected, but competitor Ionis is suing for infringement of its '333 patent. Ionis' olezarsen recently generated very strong phase 3 results in severe hypertriglyceridemia patients and these results offer positive read-through for plozasiran's phase 3 trial with data in mid-2026.

Aramark (ARMK) is upgraded to a 'BUY' rating with a maintained share price target, reflecting strong recent results and ongoing operational improvements. ARMK delivered double-digit operating income and EPS growth, record-high customer retention, and international expansion, despite market volatility and a modest dividend yield. While ARMK's fundamentals are improving, alternatives offer higher yields, lower valuations, and stronger credit ratings, making them more attractive sector picks.